New drug tested in kids for rare autoimmune disease
NCT ID NCT07222553
Summary
This study aims to understand how a drug called inebilizumab works in children with Immunoglobulin G4-related Disease (IgG4-RD), a rare condition where the immune system attacks the body's own tissues. It will enroll about 15 children aged 2 to 18 to measure the drug's levels in the body, its effect on immune cells, and its safety. The goal is to gather information to potentially control the disease and reduce the need for steroid medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN G4 RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.